Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIP5K1C | O60331 | 1/20 | 0.69 |
| ▸ | TNIK | Q9UKE5 | 11/20 | 0.55 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16700461 | 0.89 | TNIK (0.70) | TNIK | |
| SCHEMBL22468228 | 0.82 | PIP5K1C (1.00) | PIP5K1CTNIKMAPTTP53LMNA | |
| SCHEMBL2367246 | 0.78 | TNIK (0.65) | PIP5K1CTNIKMAPTTP53LMNA | |
| SCHEMBL2366947 | 0.76 | MAPT (0.56) | PIP5K1CTNIKMAPTTP53LMNA | |
| SCHEMBL13224732 | 0.76 | TNIK (0.84) | PIP5K1CTNIKMAPTTP53LMNA | |
| SCHEMBL3395871 | 0.76 | EPHX2 (0.58) | EPHX2KDM4EMEN1NPC1RAB9A | |
| SCHEMBL4922825 | 0.75 | NPC1 (0.58) | PIP5K1CEPHX2KDM4EMEN1NPC1 | |
| SCHEMBL4866294 | 0.73 | EPHX2 (0.97) | EPHX2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL3822162 | 0.72 | EPHX2 (1.00) | EPHX2NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL16707029 | 0.72 | TNIK (0.92) | PIP5K1CTNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364149-B1 | TNIK INHIBITOR AND THE USE | NAT CANCER CT (JP) | 2014-05-07 | — | — | EP | disclosed |
| EP-2364149-A1 | TNIK INHIBITOR AND THE USE | National Cancer Center (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-20100216795-A1 | TNIK INHIBITOR AND THE USE | YAMADA TESSHI | 2010-08-26 | — | — | US | disclosed |
| WO-2010064111-A1 | TNIK INHIBITOR AND THE USE | YAMADA TESSHI (JP) | 2010-06-10 | — | — | WO | disclosed |
| US-20100137386-A1 | TNIK INHIBITOR AND THE USE | YAMADA TESSHI | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216795-A1 | TNIK INHIBITOR AND THE USE | TNIK, TNNI3K, TNK1 | PIP5K1C 352/4885TNIK 1/4885MAPT 3204/4885 |
| US-20100137386-A1 | TNIK INHIBITOR AND THE USE | TNIK, TNNI3K, TNK1 | PIP5K1C 231/4885TNIK 1/4885MAPT 2295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.